Amgen in Spain Other Websites PRESS WORK WITH US CONTACT ABOUT AMGEN OUR SCIENCE PATHOLOGIES BIOSIMILARS BIOSIMILARS We work daily to guarantee access for patients with serious diseases to more treatment options by developing high-quality biosimilars Our Commitment to Biosimilars Our nearly four decades developing biological drugs to respond to some of the most serious diseases, now allow us to open a new chapter in our history and apply all our scientific knowledge in the production of high quality biosimilars. We continue to be at the forefront of biotechnology and that is why we work to discover new solutions that improve the lives of patients. At present, we are expanding our portfolio with the clinical development of a new portfolio of biosimilar drugs for the diseases that present the most therapeutic needs worldwide, mainly of an oncological and inflammatory nature. With the production of biosimilars, we strengthen our commitment to contribute to facilitating patient access to more treatment options, while offering healthcare professionals more therapeutic alternatives to tackle the most complex diseases. Likewise, its development allows us to guarantee the sustainability of the health system, reducing the cost of medical care and promoting innovation in clinical practice. What is a biosimilar? A biosimilar is a biological drug highly similar to another already approved biological drug. However, unlike generics, which are an identical copy of the reference drug, a biosimilar is not identical to the original drug. A diferencia de un genérico, un biosimilar tarda entre ocho y diez años en desarrollarse, mientras que un genérico oscila entre los tres y cinco años. Para que la Comisión Europea autorice su comercialización, tiene que demostrar que es tan seguro y efectivo como el medicamento de referencia. De ahí que se evalúe la comparabilidad en términos de propiedades, calidad, eficacia, y seguridad con el fármaco original.1 A la hora de administrarlo a los pacientes, debe ser el médico quien tome la decisión de prescribirlo en base a criterios clínicos. En ningún caso se debe substituir automáticamente el fármaco original por un biosimilar sin consentimiento del médico prescriptor. References: 1 Manual for innovative medicines. Making Medicines Affordable (Medicines for Europe) Accessed December 17. 2 US Federal Trade Commission. Emerging health care issues. Accessed November 23, 2016 BIOSIMILARS Investigation and development Production About Amgen About us Mission and values Transparency Amgen in Spain Pathologies Rheumatoid arthritis Colon cancer Breast cancer Crohn's disease Hypercholesterolemia Secondary hyperparathyroidism Multiple myeloma Osteoporosis Psoriasis Primary Immune Thrombocytopenia Our Science Introduction to biotechnology Six curiosities about biotechnology Our therapeutic modalities Production Biosimilars Investigation and development Production Privacy Statement for Healthcare Professionals Press Work with us Follow us on Contact us © 2017-2020 Amgen S.A. Todos los derechos reservados. Fecha de la última actualización: 11 de mayo de 2020 Política de Privacidad Aviso legal